Non-Small Cell Lung Cancer study: Ivonescimab
Official title A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07594522
What this study is testing
What is Ivonescimab?
An investigational intravenous medicine being studied as a potential treatment for non‑small cell lung cancer after standard stereotactic body radiotherapy.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if ivonescimab works after stereotactic body radiotherapy in patients with non‑small cell lung cancer.
- Who it's for
- Adults with non‑small cell lung cancer who have received standard SBRT.
- What's involved
- Participants will receive ivonescimab and attend scheduled visits for monitoring and tests.
- Time commitment
- The study lasts several months, with multiple clinic visits and follow‑up appointments.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients must have pathologically confirmed non-small cell lung cancer
- Early Stage NSCLC Stage IA2 - IIA (tumor size \> 1cm and ≤ 5cm, N0M0), select IIB (tumor size \>5cm and ≤ 7cm, N0M0).
- No known sensitizing EGFR or ALK alterations
- Disease amenable to 3, 5 or 8 fraction SBRT as judged by treating radiation oncologist.
- No primary tumor (Gross Target Volume, GTV) that contacts the esophagus
See the full eligibility criteria
Who can join
- Patients must have pathologically confirmed non-small cell lung cancer
- Early Stage NSCLC Stage IA2 - IIA (tumor size \> 1cm and ≤ 5cm, N0M0), select IIB (tumor size \>5cm and ≤ 7cm, N0M0). Multiple (up to 2) primary lung cancers allowed.
- No known sensitizing EGFR or ALK alterations
- Disease amenable to 3, 5 or 8 fraction SBRT as judged by treating radiation oncologist. Tumors that have extensive overlap with the mediastinum for which a more protracted radiotherapy course (i.e.
- No primary tumor (Gross Target Volume, GTV) that contacts the esophagus
- Unwilling to undergo surgical resection or ineligible for surgical resection as determined by review of a multidisciplinary team for surgical candidacy
- Patients with isolated parenchymal recurrences should have completed all prior definitive therapy (surgery, radiotherapy, chemotherapy) for at least 6 months
- No prior receipt of immune checkpoint inhibitors
- No prior thoracic radiation that precludes definitive SBRT of current disease
- Age ≥ 18
- ECOG Performance Status of ≤ 1
- Not Pregnant and Not Nursing
- Female patients of childbearing age must have negative serum pregnancy test results
- Female patient of childbearing potential having sex with an unsterilized male partner must agree to use a highly effective method of contraception from the beginning of screening until 90 days after the last dose of the...
- Unsterilized male patient having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 90 days after the last dose of ivonescimab
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3
- Platelets ≥ 100,000 cells/mm\^3
- Hemoglobin ≥ 9 g/dl
- Adequate coagulation parameters
- prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 x ULN
- partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy) This applies only to patients who are not on therapeutic...
- Urine protein \< 2+ or 24hour urine protein quantification \< 1.0g
- Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula CrCl (mL/min) = [140 - age (years)] x weight (kg) {x 0.85 for female patients} 72 creatinine (mg / dL)
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
- AST and ALT ≤2.5 x institutional ULN
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association...
- To be eligible for this trial, patients should be class 2B or better
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or how well it works assessment of the investigational regimen are eligible for...
- No active or prior documented autoimmune or inflammatory disorders, including inflammatory bowel disease (e.g., colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), systemic lupus...
- Vitiligo or alopecia
- Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Patients not on biologic therapy without active disease in the last 2 years may be included, but only after consultation with the study physician
- Patients with celiac disease controlled by diet alone
- No history of allogenic organ transplantation with exception of corneal transplantation
- No history of idiopathic pulmonary fibrosis or evidence of interstitial lung disease on imaging
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Active or recurrent hepatic disorders including cirrhosis, hepatitis B and C. Patients with a past or resolved HBV infection, defined as the presence of hepatitis B core antibody (anti-HBc) and absence of hepatitis B...
- Active tuberculosis infection (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice)
- Human Immunodeficiency Virus (positive HIV 1/2 antibodies).
- Active chronic infections requiring systemic therapy.
- History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months of enrollment
- History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event , as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 6.0, transient...
- History of perforation of the gastrointestinal tract and/or fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection...
- Acute exacerbation if COPD requiring hospitalization in the last 4 weeks
- Pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 6
- No Major surgical procedures or serious trauma within 4 weeks prior to enrolment, or plans for major surgical procedures within 4 weeks after the first dose.
- No poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy
- Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots) ° Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.
- Nasal bleeding /epistaxis (bloody nasal discharge is allowed)
- Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to randomization is not allowed.
- Concomitant Medications
- No treatment with a monoclonal antibody within 4 weeks prior to study treatment Day 1 (intraocular bevacizumab is acceptable).
- No biologic drugs targeting the immune system (e.g., TNF blockers, anakinra, abatacept, tocilizumab) within 4 weeks prior to study treatment Day 1
- No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or...
- No current or prior use of a systemic immunosuppressive medication within 4 weeks prior to study treatment Day 1. The following are exceptions to this criterion: i.
- Allergies
- No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
The study team makes the final eligibility decision.
Where it is enrolling
- Basking Ridge, New Jersey, United States
- Middletown, New Jersey, United States
- Montvale, New Jersey, United States
- Commack, New York, United States
- Harrison, New York, United States
- New York, New York, United States
- Uniondale, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Basking Ridge, New Jersey, United States; Middletown, New Jersey, United States; Montvale, New Jersey, United States; Commack, New York, United States; Harrison, New York, United States; New York, New York, United States and 1 more location. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.